Amir F Heshmatpour, president of NeonC Technologies Holdings, Inc. (NASDAQ: NTHI), reported two insider purchases of the company’s common stock in separate transactions on April 8 and April 9, 2026, according to a Form 4 filed with the Securities and Exchange Commission.
The filings show Heshmatpour acquired 10,000 shares on April 8 and an additional 5,000 shares on April 9, for a total of 15,000 shares. The aggregate consideration for the two purchases is approximately $82,000. The disclosure lists the price range paid for the shares as between $5.19 and $5.605. The April 8 purchase of 10,000 shares was executed at prices between $5.57 and $5.64, per the Form 4.
At the time of the reporting, NeonC Technologies’ common stock was trading at $5.12. The company’s share price has declined nearly 10 percent over the past week and roughly 55 percent over the prior six months.
Following these transactions, Heshmatpour directly holds 3,032,000 shares of NeonC common stock. The filing also notes he maintains indirect holdings through entities HCWG LLC, KIG LLC and AFH Holdings & Advisory, LLC.
These insider purchases occur amid several other corporate developments disclosed by NeonC Technologies. The company said it completed a private investment in public equity, or PIPE, that raised about $16 million by selling in excess of two million shares of common stock along with accompanying warrants. The filing indicates the PIPE proceeds were raised recently, but does not provide further detail on the investors or the warrant terms.
NeonC also disclosed it reached a settlement with Fox Infused, LLC, agreeing to a payment of $737,920.77. The settlement resolves a dispute that followed the termination in April 2023 of an agreement between NeonC and a subsidiary related to product supply and patent licensing.
In addition to the financing and legal developments, NeonC appointed David Choi as Chief Accounting Officer. According to the company, Choi will be responsible for oversight of accounting, financial reporting and internal controls.
Separately, NeonC said it will present initial data from its NEO212-01 Phase 1/2 clinical trial on March 4, 2026. The presentation is expected to include safety and toxicity results and observations from dose-escalation cohorts.
These disclosures, taken together, show insider buying against a backdrop of capital raising, litigation resolution and clinical milestones. The Form 4 filing documenting Heshmatpour’s purchases is the primary source for the insider transaction details.